Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine is a Conjugate Vaccine owned by GSK, and is involved in 62 clinical trials, of which 58 were completed, and 4 are ongoing.

Neisseria meningitidis is a gram-negative diplococcus which causes meningitis and sepsis. Globally, 5 serogroups, A, B, C, Y and W-135 cause almost all invasive meningococcal infections. The presence of serum bactericidal antibodies protects against invasive meningococcal disease. Vaccination with menveo leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.

The revenue for Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine is expected to reach a total of $4.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine NPV Report.

Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine was originated by Novartis and is currently owned by GSK. CanSino Biologics is the other company associated in development or marketing of Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine.

Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine Overview

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine) (Menveo / Menivact / Menhycia) is a sterile liquid vaccine. It is formulated as lyophilized powder for injection and injection solution for intramuscular route of administration. It is indicated for active immunization to prevent meningococcal disease caused by neisseria meningitidis serogroups. It is also approved for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis) in infants and toddlers from 2 months of age. It is quadrivalent vaccine acts by producing bactericidal antibodies.

It is under development for the prevention of Neisseria meningitidis infections. It is also indicated for active immunization of infants (from two months of age) and children to prevent invasive disease caused by the bacteria Neisseria meningitidis serogroups A, C, W135 and Y1. The vaccine can also be used in adolescents and adults to help protect against the four strains of meningococcal disease contained in the vaccine.

CanSino Biologics Overview

CanSino Biologics is a biopharmaceutical company that develops, manufactures and commercializes pneumococcal, polyvalent conjugate and adenovirus-based recombinant TB vaccines. The company is investigating Ad5-EBOV, an adenovirus type 5 vector, to treat Ebola virus; MCV2 and MCV4 vaccines for the prevention of Neisseria meningitidis bacteria. It is also evaluating DTcP vaccine against pertussis caused after primary vaccination in infants and children; and PBPV, PCV13i vaccines, targeting pneumococcal diseases. CanSino Biologics utilizes Adenovirus-based viral vector vaccine, conjugation, formulation, and protein structure design and recombinant technology to develop vaccines. It works in partnership with MC Master University, National Research Council of Canada and Beijing Institute of Biotechnology. CanSino Biologics is headquartered in Tianjin, China.

The company reported revenues of (Renminbi) CNY4,299.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of CNY18.5 million in FY2020. The operating profit of the company was CNY1,911.6 million in FY2021, compared to an operating loss of CNY400.9 million in FY2020. The net profit of the company was CNY1,914.4 million in FY2021, compared to a net loss of CNY396.6 million in FY2020.

Quick View – Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine

Report Segments
  • Innovator (NME)
Drug Name
  • Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.